{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:56:50Z","timestamp":1791619010525,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007914","name":"UT Southwestern Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.adro.2025.101835","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T19:49:04Z","timestamp":1749844144000},"page":"101835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Stereotactic Radiation Therapy for the Treatment of Glandular Metastases From Renal Cell Carcinoma"],"prefix":"10.1016","volume":"10","author":[{"given":"Mihailo","family":"Miljanic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tidie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Christie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Suk","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Garant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zabihullah","family":"Wardak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Courtney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Brugarolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1282-056X","authenticated-orcid":false,"given":"Raquibul","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2025.101835_bib0001","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11864-003-0039-2","article-title":"Metastatic renal cell carcinoma","volume":"4","author":"Flanigan","year":"2003","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.adro.2025.101835_bib0002","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s12032-018-1217-1","article-title":"Contemporary treatment of metastatic renal cell carcinoma","volume":"35","author":"Wiechno","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.adro.2025.101835_bib0003","first-page":"507","article-title":"Treatment of renal cell carcinoma: Current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.adro.2025.101835_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006361","article-title":"Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma","volume":"11","author":"Rini","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.adro.2025.101835_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151662","article-title":"Clinical impact of pancreatic metastases from renal cell carcinoma: A multicenter retrospective analysis","volume":"11","author":"Grassi","year":"2016","journal-title":"PLOS One"},{"key":"10.1016\/j.adro.2025.101835_bib0006","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000455970","article-title":"Outcome of patients with renal cell carcinoma and multiple glandular metastases treated with targeted agents","volume":"92","author":"Grassi","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.adro.2025.101835_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.10.015","article-title":"Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era","volume":"34","author":"Gravis","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.adro.2025.101835_bib0008","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jnci\/djr511","article-title":"Targeted therapies for renal cell carcinoma: Review of adverse event management strategies","volume":"104","author":"Eisen","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.adro.2025.101835_bib0009","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.euo.2022.06.008","article-title":"Stereotactic ablative radiation for systemic therapy-na\u00efve oligometastatic kidney cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.adro.2025.101835_bib0010","article-title":"Stereotactic ablative radiation therapy for oligoprogressive renal cell carcinoma","volume":"6","author":"Schoenhals","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2025.101835_bib0011","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/MOU.0000000000000330","article-title":"Metastasis therapies for renal cancer","volume":"26","author":"Dabestani","year":"2016","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.adro.2025.101835_bib0012","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S1470-2045(14)70235-9","article-title":"Local treatments for metastases of renal cell carcinoma: a systematic review","volume":"15","author":"Dabestani","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2025.101835_bib0013","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","article-title":"Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): A meta-analysis of 28 studies","volume":"2","author":"Zaorsky","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.adro.2025.101835_bib0014","first-page":"29","article-title":"Stereotactic body radiation therapy (SBRT) for metastatic renal cell carcinoma: A multi-institutional experience","volume":"7","author":"Singh","year":"2020","journal-title":"J Radiosurg SBRT"},{"key":"10.1016\/j.adro.2025.101835_bib0015","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijrobp.2019.07.023","article-title":"Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer","volume":"105","author":"Zhang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2025.101835_bib0016","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2021.12.001","article-title":"Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.adro.2025.101835_bib0017","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.adro.2018.05.006","article-title":"Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity","volume":"3","author":"Toesca","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2025.101835_bib0018","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijrobp.2017.01.032","article-title":"Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases","volume":"98","author":"Wang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2025.101835_bib0019","doi-asserted-by":"crossref","first-page":"e905","DOI":"10.1002\/onco.13736","article-title":"Temporal trends and predictors in the use of stereotactic body radiotherapy for treatment of metastatic renal cell carcinoma in the U.S","volume":"26","author":"Paciotti","year":"2021","journal-title":"Oncologist"},{"issue":"Suppl 2","key":"10.1016\/j.adro.2025.101835_bib0020","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.21037\/cco.2017.06.30","article-title":"Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases","volume":"6","author":"Kothari","year":"2017","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.adro.2025.101835_bib0021","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","article-title":"Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: A phase 2 prospective multicenter study","volume":"80","author":"Cheung","year":"2021","journal-title":"Eur Urol"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109425001228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109425001228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T14:39:58Z","timestamp":1757687998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109425001228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2452109425001228"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2025.101835","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Radiation Therapy for the Treatment of Glandular Metastases From Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2025.101835","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101835"}}